The company said on June 25, 2025 it entered into an Amended and Restated Transaction Agreement with Thermo Fisher Scientific Inc. that removes the drinking water filtration business (Water Business) from the sale.

1. 01

   The company said on June 25, 2025 it entered into an Amended and Restated Transaction Agreement with Thermo Fisher Scientific Inc. that removes the drinking water filtration business (Water Business) from the sale.

2. 02

   Solventum said it lowered the cash consideration payable at closing from approximately $4.10 billion to approximately $4.00 billion and intends to use the net proceeds primarily to pay down debt. The closing price remains subject to customary adjustments for closing cash and debt, unpaid transaction expenses and working capital.

3. 03

   Solventum said Thermo Fisher Scientific Inc. may receive up to $75 million from Solventum either upon a sale of the Water Business or after an agreed 3-year period.

4. 04

   Solventum said keeping the Water Business would increase its previously estimated annual EPS accretion of 15 to 20 cents, but would reduce the previously projected improvements to gross margin and operating margin, which were 200 basis points and 100 basis points, respectively. It said it will share updated estimates during its Q2 earnings call.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.